Dr. Avak Kahvejian is a Partner at Flagship Pioneering and a serial biotech entrepreneur whose work has led to the creation of transformative public and private companies, including Seres Therapeutics, Rubius Therapeutics, Codiak BioSciences, Cygnal Therapeutics, Ring Therapeutics, Cellarity, Laronde, and Generate Biomedicines. He has served as founding CEO or senior executive for multiple Flagship companies, advancing new modalities such as exosome therapeutics, endless RNA, and generative biology.

Before joining Flagship, he commercialized the world’s first single-molecule DNA sequencer at Helicos BioSciences. Avak holds a Ph.D. and B.Sc. in Biochemistry from McGill University and serves on boards supporting immigrants, education, and scientific entrepreneurship.